LetterPoiseuille's law and large-bore needles: Insights into the delivery of corticosteroid injections in the treatment of keloids
References (5)
- et al.
Painless steroid injections for hypertrophic scars and keloids
Br J Plast Surg
(2002) - et al.
Painless steroid injections for hypertrophic scars and keloids
Br J Plast Surg
(2003)
Cited by (17)
Botulinum toxin type a intralesional monotherapy for treating human hypertrophic scar in a dose-dependent manner: In an animal model
2021, Journal of Plastic, Reconstructive and Aesthetic SurgeryCitation Excerpt :Triamcinolone is one of the most commonly used steroid for injection treating HS.13,14 However, some complications of applying steroids are hard to accept by patients, such as severe pain during injection, ulcerate in injection-site, hyperpigmentation, telangiectasia, and skin atrophy.15–18 Botulinum toxin type A (BTX-A) is another option for intralesional injection, with milder complications and less side effects.
Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics
2010, Progress in Retinal and Eye ResearchCitation Excerpt :To date however, there is not sufficient evidence to consistently demonstrate outcomes that can match those receiving monthly treatment (Bressler, 2009). The effect of needle bore size may be investigated using Poiseuille’s law which defines the flow of material in a tube system (Chuang et al., 2008) in relation to the radius of the tube. Furthermore, the needle bore size may have a secondary effect on the post-injection IOP which influences the pharmacokinetics of the IVT as discussed later.
A structured approach with Swiss cheese model to reduce vascular adverse events of filler injections
2024, Journal of Cosmetic DermatologyTopical Anesthetic versus Lidocaine Mixture for Pain Relief during Keloid Treatment: A Prospective, Split Study
2023, Journal of Craniofacial SurgeryRevisiting the Role of Local Cryotherapy for Acne Treatment: A Review and Update
2023, Journal of Clinical Medicine
Funding sources: None.
Conflicts of interest: None declared.